



Clinical trial results:

A Parallel-group Phase 4, Open-label, Two-arm Study to Assess the Safety and Efficacy of Intravitreal (IVT) Aflibercept with Proactive Customized Treatment Intervals in Patients 50 Years of Age with No Fluid Due to Choroidal Neovascularization (CNV) Lesions Secondary to Neovascular (wet) Age-related Macular Degeneration (nAMD) Following Treatment Initiation with Aflibercept

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2022-000690-73 |
| Trial protocol | DE FR ES |
| Global end of trial date | 11 July 2023 |

Results information

| | |
|--------------------------------|--------------|
| Result version number | v1 (current) |
| This version publication date | 25 July 2024 |
| First version publication date | 25 July 2024 |

Trial information

Trial identification

| | |
|-----------------------|------------------|
| Sponsor protocol code | BAY86-5321/21912 |
|-----------------------|------------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT05473715 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Bayer AG |
| Sponsor organisation address | Kaiser Wilhelm Allee, Leverkusen, Germany, D-51368 |
| Public contact | Therapeutic Area Head, Bayer AG, 49 30 300139003, clinical-trials-contact@bayer.com |
| Scientific contact | Therapeutic Area Head, Bayer AG, 49 30 300139003, clinical-trials-contact@bayer.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|--------------|
| Analysis stage | Final |
| Date of interim/final analysis | 11 July 2023 |
| Is this the analysis of the primary completion data? | No |

| | |
|----------------------------------|--------------|
| Global end of trial reached? | Yes |
| Global end of trial date | 11 July 2023 |
| Was the trial ended prematurely? | Yes |

Notes:

General information about the trial

Main objective of the trial:

To assess whether 2 mg IVT aflibercept administered at a customized treatment interval (determined after the first extended treatment interval) is non-inferior to 2 mg IVT aflibercept administered according to a standard T&E regimen (initiated after the first extended treatment interval) in patients with no fluid following treatment initiation for nAMD

Protection of trial subjects:

The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki and the International Council for Harmonization guideline E6: Good Clinical Practice. Before entering the study, the informed consent was read by and explained to all the subjects. Participating subjects signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy: -

Evidence for comparator: -

| | |
|---|---------------|
| Actual start date of recruitment | 25 April 2023 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------------|
| Country: Number of subjects enrolled | United Kingdom: 1 |
| Country: Number of subjects enrolled | Canada: 2 |
| Worldwide total number of subjects | 3 |
| EEA total number of subjects | 0 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |

| | |
|---------------------------|---|
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 1 |
| 85 years and over | 2 |

Subject disposition

Recruitment

Recruitment details:

Study enrolled subjects in 2 countries, between 25 Apr 2023 (first subject first visit) and 11 Jul 2023 (termination date).

Pre-assignment

Screening details:

Four subjects were screened; 3 were randomized and treated.

Period 1

| | |
|------------------------------|--------------------------|
| Period 1 title | Overall (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|-------------------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Customized treatment interval |

Arm description: -

| | |
|--|------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Aflibercept |
| Investigational medicinal product code | BAY 86-5321 |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intravitreal use |

Dosage and administration details:

2 mg intravitreal (IVT) injection, initial injection was at baseline, maintain injection interval is 16 weeks.

| | |
|------------------|--------------|
| Arm title | Standard T&E |
|------------------|--------------|

Arm description: -

| | |
|--|-------------------|
| Arm type | Active comparator |
| Investigational medicinal product name | Aflibercept |
| Investigational medicinal product code | BAY 86-5321 |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intravitreal use |

Dosage and administration details:

2 mg IVT injection, initial injection is at baseline, maintain injection intervals is 8 weeks or adjusted in 2 weeks increments each time (up to a maximum of 16 weeks and minimum of 4 weeks).

| Number of subjects in period 1 | Customized treatment interval | Standard T&E |
|--------------------------------|-------------------------------|--------------|
| Started | 2 | 1 |
| Completed | 0 | 0 |
| Not completed | 2 | 1 |
| Trial terminate | 2 | 1 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|---------|
| Reporting group title | Overall |
|-----------------------|---------|

Reporting group description: -

| Reporting group values | Overall | Total | |
|---|---------|-------|--|
| Number of subjects | 3 | 3 | |
| Age Categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 0 | 0 | |
| From 65-84 years | 1 | 1 | |
| 85 years and over | 2 | 2 | |
| Gender Categorical | | | |
| Units: Subjects | | | |
| Female | 1 | 1 | |
| Male | 2 | 2 | |

End points

End points reporting groups

| | |
|--------------------------------|-------------------------------|
| Reporting group title | Customized treatment interval |
| Reporting group description: - | |
| Reporting group title | Standard T&E |
| Reporting group description: - | |

Primary: Change in best-corrected visual acuity (BCVA) (early treatment diabetic retinopathy study [ETDRS] letters)

| | |
|-----------------|---|
| End point title | Change in best-corrected visual acuity (BCVA) (early treatment diabetic retinopathy study [ETDRS] letters) ^[1] |
|-----------------|---|

End point description:

Visual function was assessed using the ETDRS protocol (Early Treatment Diabetic Retinopathy Study Research Group, 1985). Visual acuity examiners must be certified to ensure consistent measurement of BCVA.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From baseline to Week 36

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no statistical analyses were performed.

| End point values | Customized treatment interval | Standard T&E | | |
|-----------------------------|-------------------------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0 ^[2] | 0 ^[3] | | |
| Units: Letter scale | | | | |
| number (not applicable) | | | | |

Notes:

[2] - Study early terminated.

[3] - Study early terminated.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)

| | |
|-----------------|--|
| End point title | Number of subjects with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) |
|-----------------|--|

End point description:

AEs that occurred or worsened after the first injection of study drug and no later than 30 days after the last injection of study drug was considered as treatment-emergent adverse events (TEAEs).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to weeks 36 and 52

| End point values | Customized treatment interval | Standard T&E | | |
|-----------------------------|-------------------------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 2 | 1 | | |
| Units: Subjects | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of IVT aflibercept injections per patient until Week 36

| | |
|------------------------|--|
| End point title | Number of IVT aflibercept injections per patient until Week 36 |
| End point description: | Subject took aflibercept on study eye. |
| End point type | Secondary |
| End point timeframe: | Up to week 36 |

| End point values | Customized treatment interval | Standard T&E | | |
|-----------------------------|-------------------------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 2 | 1 | | |
| Units: Injections | 1 | 1 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of patients achieving pre-defined treatment intervals

| | |
|------------------------|--|
| End point title | Number of patients achieving pre-defined treatment intervals |
| End point description: | Pre-defined treatment intervals are: ≥ 4 , ≥ 8 , ≥ 10 , ≥ 12 , ≥ 14 , and 16 weeks. |
| End point type | Secondary |
| End point timeframe: | At Weeks 36 and 52 |

| End point values | Customized treatment interval | Standard T&E | | |
|-----------------------------|-------------------------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0 ^[4] | 0 ^[5] | | |
| Units: Subjects | | | | |

Notes:

[4] - Study early terminated.

[5] - Study early terminated.

Statistical analyses

No statistical analyses for this end point

Secondary: Change in BCVA (ETDRS letters)

| | |
|-----------------|--------------------------------|
| End point title | Change in BCVA (ETDRS letters) |
|-----------------|--------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From baseline to week 52

| End point values | Customized treatment interval | Standard T&E | | |
|-----------------------------|-------------------------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0 ^[6] | 0 ^[7] | | |
| Units: Letter score | | | | |
| number (not applicable) | | | | |

Notes:

[6] - Study early terminated.

[7] - Study early terminated.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of IVT aflibercept injections per patient up to Week 52

| | |
|-----------------|--|
| End point title | Number of IVT aflibercept injections per patient up to Week 52 |
|-----------------|--|

End point description:

Subject took aflibercept on study eye.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to week 52

| | | | | |
|-----------------------------|-------------------------------|-----------------|--|--|
| End point values | Customized treatment interval | Standard T&E | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 2 | 1 | | |
| Units: Injections | 1 | 1 | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

After the first injection of study drug and no later than 30 days after the last injection of study drug, up to 78 days.

Adverse event reporting additional description:

Adverse event reporting for the deaths (all causes) considers all deaths that occurred at any time during the study before the last contact, up to 78 days.

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 26.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|--------------|
| Reporting group title | Standard T&E |
|-----------------------|--------------|

Reporting group description: -

| | |
|-----------------------|-------------------------------|
| Reporting group title | Customized treatment interval |
|-----------------------|-------------------------------|

Reporting group description: -

| Serious adverse events | Standard T&E | Customized treatment interval | |
|---|---------------|-------------------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 2 (0.00%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | 0 | 0 | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Standard T&E | Customized treatment interval | |
|---|---------------|-------------------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 2 (0.00%) | |

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: No non-serious adverse events collected due to low number of participants.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

| |
|---|
| The trial was terminated due to administrative reasons not related to efficacy or safety. |
|---|

Notes: